

Standard Contractual Clauses (SCC) for Clinical Trials in Germany – A New Approach

 Date: **Wednesday, July 1st, 2026**, 4 – 5.30 pm Berlin time (CEST)
(respectively 10 – 11.30 am EDT or 7 – 8.30 am PDT)

 Location: **Online** (Webinar in English)

 [Registrationform](#)

Clinical trial contracting in Germany is evolving — are you prepared for what comes next?

Join our upcoming webinar to explore the latest developments and emerging approaches surrounding the new Standard Contractual Clauses (SCC) for clinical trials in Germany. As regulatory expectations, negotiation dynamics, and operational demands continue to change, standardized contracting models are becoming increasingly important for sponsors, CRO, and trial sites alike.

In our webinar, experts will discuss:

- Current challenges in clinical trial contract negotiations in Germany,
- The rationale behind new standardized approaches,
- Key legal and operational considerations,
- Basic comparison US-law vs. German Law,
- Practical implications for sponsors, CRO, and trial sites,
- Opportunities to accelerate study start-up timelines through harmonized contracting.

Whether you are involved in legal, clinical operations, or study management, this session will provide valuable insights into the future of clinical trial agreements in Germany.

Stay ahead of the curve and join the discussion.

PROGRAM

Welcome/Introduction (DHM/vfa)

The new Standard Contractual Clauses in Germany

(Dr. Lars Nickel; Head of Sub-Division 11; German Ministry of Health – tbc) – 15 Minutes

Why is this important for industrial sponsors, and why does this German approach differ from US law?

(Christoph Bertsch; Senior Counsel Drug Development & Regulatory Law; Bristol Myers Squibb) – 15 Minutes

How do universities and study centres in Germany view the Standard Contractual Clauses?

(tbd – Law graduate from a trial site) – 10 Minutes

Open round for discussion and your questions on Standard Contractual Clauses in Germany – 40 Minutes

Closing remarks and Farewell

Registration is available via this [online form](#).

Disclaimer:

Please note that this webinar will be recorded. By participating in the live session, you acknowledge that any questions or comments raised during the discussion may be included in the recording. This may include your name, voice, and/or video image if you choose to actively participate.

This webinar is jointly organized by leading German associations and networks representing the pharmaceutical industry, clinical research organizations, academic medicine, and clinical trial infrastructure:

- **German University Medicine e.V. (DHM):** The DHM (Deutsche Hochschulmedizin e.V.) is the umbrella organisation representing Germany's 37 academic medical centres and 40 medical faculties. Academic Medical Centres provide healthcare at the highest level of quality by integrating patient care with medical research and clinical training. They are also particularly well equipped to treat complex cases, including rare diseases. Their interests are represented by the [German Association of Academic Medical Centres](#) (VUD). Their academic partners, the 40 German medical faculties, focus on advancing medical and educational research and on training the next generation of physicians. They are represented by the [German Association of Medical Faculties](#) (MFT). Together, the VUD and MFT founded the DHM to represent their shared interests in political decision-making and to help shape the framework conditions of the German health care system.
- **KKS-Netzwerk e.V. (KKS):** KKS brings together Coordination Centres for Clinical Trials (KKS) and Clinical Trial Centres (ZKS) with the aim of further developing patient-centred clinical research in Germany. The KKS-Netzwerk currently has 27 members, all of which are established as independent departments at university sites.
- **Verband der forschenden Pharma-Unternehmen e.V. (vfa):** The vfa represents the interests of 49 world-leading research-based pharmaceutical companies with over 100 subsidiaries and affiliates. The members of the vfa account for more than two-thirds of the total German pharmaceutical market and employ approximately 94,000 people in Germany. In Germany alone, our members invest €8.7 billion annually in pharmaceutical research.
- **Bundesverband der Pharmazeutischen Industrie e.V. (BPI):** The German Pharmaceutical Industry Association (BPI) is an alliance of pharmaceutical companies representing the industry across the entire value chain in Germany and Europe. Together with our members, we are committed to improving people's health and quality of life. The BPI represents its 270 member companies and their approximately 78,000 employees.
- **Bundesverband Medizinischer Auftragsinstitute e.V. (BVMA):** The Federal Association of Medical Contract Research Organisations (BVMA) e.V. is the representative body for German-speaking CROs (Contract Research Organisations). The BVMA represents 51 CROs operating both nationally and internationally (as of October 2025). With around 8,000 employees, the member companies thus account for more than 80% of the workforce in the German CRO market.
- **Pharma Deutschland e.V.:** represents the interests of the pharmaceutical and medical devices industry at both federal and state level in dealings with politicians, regulatory authorities and healthcare institutions. Its advocacy work and support for members cover the fields of prescription and non-prescription medicines, as well as medical devices such as medical apps and digital health applications.
- **Bundesverband Medizintechnologie e.V. (BVMed):** The German Medical Technology Association is the leading association for the medtech sector in Germany. It promotes and represents the interests of over 300 medtech companies in dealings with policymakers and the public. Its membership comprises German and international medical technology manufacturers, distributors and suppliers, as well as providers of medical aids and home care services.





DEUTSCHE HOCHSCHULMEDIZIN E.V.



VERBAND DER
UNIVERSITÄTSKLINIKEN
DEUTSCHLANDS



medizinischer
fakultätentag



By bringing together expertise from across the clinical research landscape, the organizers aim to foster practical dialogue and collaborative solutions for the future of clinical trial contracting in Germany.